Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves blood sugar control. It is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and is the highest-revenue peptide therapeutic to date.

Semaglutide is a long-acting synthetic analog of glucagon-like peptide-1 (GLP-1), an incretin hormone naturally secreted by intestinal L-cells in response to food intake. Developed by Novo Nordisk, it is FDA-approved under two brand names: Ozempic (0.5–2 mg weekly subcutaneous) for type 2 diabetes management and cardiovascular risk reduction, and Wegovy (2.4 mg weekly subcutaneous) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. An oral formulation, Rybelsus (3–14 mg daily), is approved for type 2 diabetes and uses a sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC) absorption enhancer to achieve clinically meaningful oral bioavailability — a first for GLP-1 receptor agonists. As of 2025, semaglutide products generate over $20 billion in annual revenue, making semaglutide the highest-revenue peptide therapeutic in pharmaceutical history.

Structurally, semaglutide is a 31-amino-acid peptide (94% sequence homology with human GLP-1) with three critical modifications engineered for once-weekly dosing: a lysine-34 to arginine substitution preventing DPP-IV cleavage at position 8, an alanine-8 substitution for the same purpose, and a C-18 fatty diacid chain attached via a short linker to lysine-26. This lipid modification promotes reversible albumin binding in plasma, reducing renal clearance and extending the half-life from native GLP-1's 2 minutes to approximately 7 days — enabling once-weekly dosing with sustained therapeutic plasma concentrations.

Beyond weight loss and glycemic control, semaglutide has demonstrated cardiovascular benefits that distinguish it from older diabetes drugs. The SUSTAIN-6 trial (3,297 patients with T2D at high cardiovascular risk) showed a 26% reduction in major adverse cardiovascular events (MACE). The subsequent SELECT trial (17,604 patients without diabetes but with obesity and established cardiovascular disease) demonstrated a remarkable 20% reduction in MACE — establishing GLP-1 receptor agonism as a cardioprotective drug class independent of its metabolic effects. Emerging research also suggests efficacy in non-alcoholic steatohepatitis (NASH), Alzheimer's disease (neuroinflammation reduction), and substance use disorder (addiction circuitry overlap with appetite regulation).

Semaglutide's commercial trajectory has reshaped the pharmaceutical landscape. Wegovy shortages following its 2021 launch forced rationing, spawned a compounding pharmacy industry that the FDA has been actively contesting since 2024, and catalyzed a competitive response from multiple pharmaceutical companies now racing to develop next-generation GLP-1/GIP dual agonists (tirzepatide), GLP-1/glucagon dual agonists (survodutide), and oral GLP-1 analogs (orforglipron). The drug's success has also prompted off-label use in populations without obesity or diabetes — a pattern that raises both ethical and supply-chain questions that regulators are actively navigating.

Semaglutide's therapeutic effects arise from agonism at the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR) coupled to Gs proteins. Upon binding, semaglutide activates adenylyl cyclase, elevating intracellular cAMP, which activates protein kinase A (PKA) and downstream signaling cascades that differ by tissue type.

In pancreatic beta cells, PKA phosphorylates CREB and promotes translocation of insulin secretory granules to the plasma membrane — increasing insulin secretion specifically in response to glucose (glucose-dependent insulinotropia). Simultaneously, GLP-1R agonism in pancreatic alpha cells suppresses glucagon secretion, reducing hepatic glucose output. The combined effect is substantially improved glycemic control without the hypoglycemia risk of sulfonylureas (which force insulin secretion regardless of glucose levels). Beta cell mass preservation — observed in animal models via reduced apoptosis and increased proliferation — is a mechanistically important effect that may slow T2D progression, though its translation to humans over multi-year treatment remains under investigation.

In the central nervous system, GLP-1R is expressed in the hypothalamic arcuate nucleus, the nucleus of the solitary tract (NTS), and the area postrema — brain regions governing appetite, satiety, and autonomic function. Semaglutide activates pro-opiomelanocortin (POMC) neurons and inhibits neuropeptide Y (NPY)/AgRP neurons in the arcuate nucleus, shifting the hypothalamic energy balance set point toward satiety. GLP-1R activation in the NTS signals meal-induced fullness via vagal afferent pathways. Together, these central effects reduce caloric intake by 20–30% in treated patients — a magnitude comparable to surgical interventions.

Gastric emptying is slowed via GLP-1R in the enteric nervous system and vagal efferents, contributing to early satiety (smaller meal volume before fullness) and reduced postprandial glucose excursions. Cardiovascular benefits appear to involve GLP-1R in cardiac muscle, vascular endothelium, and macrophages: anti-inflammatory effects, reduced foam cell formation in atherosclerotic plaques, improved endothelial function, and mild reduction in heart rate (3–5 bpm) and blood pressure (2–4 mmHg systolic) all contribute to the MACE risk reduction observed in SELECT and SUSTAIN-6.

Semaglutide has the most extensive randomized controlled trial evidence base of any peptide therapeutic. The STEP (Semaglutide Treatment Effect in People with Obesity) program comprises six Phase III RCTs totaling over 10,000 participants. STEP 1 (Wilding et al., N Engl J Med, 2021; n=1,961 adults with obesity) is the flagship: semaglutide 2.4 mg weekly for 68 weeks produced mean body weight reduction of 14.9% versus 2.4% placebo. STEP 2 (n=1,210, T2D comorbidity) showed 9.6% weight loss in the diabetes population. STEP 3 (n=611, intensive behavioral counseling co-intervention) achieved 16.0%. STEP 4 (continued vs. withdrawn at 20 weeks) demonstrated that weight regain occurs rapidly upon discontinuation — a finding with major implications for long-term treatment duration. STEP 5 (104-week data) confirmed durability at 15.2% weight loss, establishing that benefits are sustained during continued therapy.

The SELECT trial (Lincoff et al., N Engl J Med, 2023; n=17,604) is the landmark cardiovascular outcomes study. It enrolled adults with pre-existing cardiovascular disease and overweight/obesity but without diabetes — a population not historically treated with GLP-1 agents. Semaglutide 2.4 mg weekly reduced the primary endpoint (composite of cardiovascular death, non-fatal MI, non-fatal stroke) by 20% over a median follow-up of 33.6 months. This was the first trial to demonstrate cardiovascular mortality reduction from a GLP-1 RA in a non-diabetic population, establishing GLP-1R agonism as a cardioprotective drug class rather than merely a metabolic intervention.

The SUSTAIN-6 trial (Marso et al., N Engl J Med, 2016; n=3,297) evaluated cardiovascular safety in T2D patients at high cardiovascular risk, demonstrating a 26% reduction in MACE with semaglutide 0.5 or 1 mg versus placebo. A specific finding — significant reduction in stroke events — distinguished semaglutide from other GLP-1 agents in the class.

For the oral formulation, the PIONEER program (10 trials) established the efficacy and safety of oral semaglutide 14 mg daily in T2D, with non-inferiority to injectable semaglutide on HbA1c reduction and moderate weight loss (4.4 kg). The OASIS 1 trial (2023) extended oral semaglutide 50 mg into weight management, with 17.4% weight reduction at 68 weeks — establishing that the oral route can approach injectable efficacy at higher doses.

Emerging data from NASH trials (ESSENCE, ongoing), Alzheimer's disease observational analyses (Nørgaard et al., ALZ, 2024), and addiction studies (reduced alcohol craving in multiple small trials) represent active frontiers. The mechanistic overlap between GLP-1R signaling in the mesolimbic reward system and the pathways involved in addiction has generated substantial scientific interest, with several Phase II trials in alcohol use disorder and opioid use disorder underway.[1][2][3][4][5]

Peptides commonly paired with Semaglutide for synergistic effects.